23 Jan 2017

URGENT FIELD SAFETY NOTICE
FSCA3303

ETEST® XM256 (Cefuroxime) Foam (Ref. 506958, 506918) and SPB (Ref. 412304, 412305)

Dear Customer

Our records indicate that your laboratory has received the following products. This letter is intended for all ETEST® XM256 (Cefuroxime) Foam (Ref. 506958, 506918) and SPB (Ref. 412304, 412305) users (product reference and lot numbers included below).

Product References impacted:

Reference	Description	Lot Number	Expiry date
412304	**ETEST® XM256 (Cefuroxime)** US SPB	1004497830	02-Dec-18
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1002884720	16-Jan-17
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1003028270	20-Mar-17
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1003075500	09-Apr-17
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1003383650	27-Aug-17
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1004018820	19-May-18
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1004497810	02-Dec-18
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1005161160	15-Sep-19
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1002884980	16-Jan-17
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1003028290	20-Mar-17
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1003075850	09-Apr-17
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1003385930	27-Aug-17
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1003396150	02-Sep-17
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1004022170	19-May-18
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1004498100	02-Dec-18
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1005161470	15-Sep-19
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1002885010	16-Jan-17
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1003075540	09-Apr-17
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1003396550	02-Sep-17
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1004019050	19-May-18
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1004501930	02-Dec-18
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1005161480	15-Sep-19

bioMérieux UK Ltd

Grafton Way, Basingstoke, Hampshire, RG22 6HY
Tel.: +44 (0)1256 461881 - Fax: +44 (0)1256 816863 - www.biomerieux.co.uk
Registered Office: Grafton Way, Basingstoke, Hampshire, RG22 6HY – Registered in England No. 1061914

Description of the issue

An analysis was performed on the Essential Agreement rate reflecting the MIC result obtained by the product for a significant strains kit including *Enterobacteriaceae, Haemophilus* and *S. pneumoniae*. Species. Then, an additional analysis was done on the clinical categorization of the strains based on CLSI guidance. The following have been identified:

⇨ The investigation confirmed a potential performance issue on strains categorization **for *Streptococcus pneumoniae* and for *Enterobacteriaceae* strains limited to oral cefuroxim breakpoints and based on 2016 CLSI clinical standards only:**

- **For *Streptococcus pneumoniae*** on ETEST® XM256 (Cefuroxime) FOAM and SPB that could lead to minor error on clinical strains :
  - False Susceptible result instead of Intermediate results with BMD (Broth Micro Dilution) reference method
  - False Intermediate result instead of Resistant results with BMD reference method

- **For Enterobacteriaceae** on ETEST® XM256 (Cefuroxime) FOAM and SPB that could lead to minor error on clinical strains:
  - False Susceptible result instead of Intermediate results with AD (Agar Dilution) reference method
  - False Intermediate result instead of Resistant results with AD reference method

⇨ Products perform within the specification when using the 2016 EUCAST guidelines.

Impact to Patient/User:

As the result of the referenced issue, the potential hazard is to obtain Minor error (**Susceptible instead of Intermediate or Intermediate instead of Resistant) on strain categorization for *Streptococcus pneumoniae* and for *Enterobacteriaceae* strains only when using the 2016 CLSI clinical breakpoints defined for cefuroxime oral forms.**

- For ***Streptococcus pneumoniae* strains and only when oral breakpoints are used** (not parenteral breakpoints) **for Cefuroxime**: **based on 2016 clinical CLSI guidelines**, a reduced MIC value could be obtained with ETEST® XM256 SPB and FOAM packaging that could lead to a susceptible categorization instead of intermediate categorization (Minor Error) or intermediate categorization instead of resistant

categorization (minor Error) for clinical strains compared to broth microdilution (BMD) reference method.

 For ***Enterobacteriaceae*** **strains and only when oral breakpoints are used** (not parenteral breakpoints) **for Cefuroxime: based on 2016 CLSI clinical guidelines,** a reduced MIC value could be obtained with ETEST® XM256 SPB and FOAM that could lead to a susceptible categorization instead of intermediate categorization (Minor Error) or intermediate categorization instead of resistant categorization (minor Error) for clinical strains compared to Agar dilution (AD) reference method

Cont.

Required actions:

- Please distribute this information to all appropriate personnel in your laboratory, retain a copy in your files, and forward this information to all parties that may use this product, including others to whom you may have transferred our product.

- **Recommendations only for users under 2016 CLSI clinical guidelines,:**

  Laboratories can continue to use ETEST® XM256 SPB and FOAM **and can directly report the results** for *Streptococcus pneumoniae* and Enterobacteriaceae **when oral breakpoints are used when applying the following recommendations**:

Cefuroxime oral breakpoints	
Streptococcus pneumoniae	**Enterobacteriaceae**
→Cefuroxime Results can be directly reported for ○ Isolate tests penicillin susceptible (MIC≤0.06 µg/ml) and cefuroxime susceptible (**ETEST® XM256** MIC ≤1 µg /ml) ○ Isolate tests penicillin resistant (MIC ≥0.12 µg/ml) and cefuroxime resistant (**ETEST® XM256** ≥ 4 µg /ml) ○ Isolate tests cefuroxime resistant (**ETEST® XM256** ≥ 4 µg /ml) **→ the cefuroxime MIC should be confirmed using an alternative MIC test method for** ○ isolates testing penicillin resistant (MIC ≥0.12 µg/ml) and cefuroxime susceptible (ETEST® XM256 MIC ≤1µg/ml) or intermediate (ETEST® XM256 MIC = 2µg/ml),	**→Cefuroxime Results can be directly reported for** ○ Isolate tests cefazolin **(*)** susceptible (MIC ≤16 µg/ml) and cefuroxime susceptible (**ETEST® XM256** MIC ≤4 µg /ml) ○ Isolate tests cefuroxime resistant (**ETEST® XM256** ≥ 32 µg /ml) **→the cefuroxime MIC should be confirmed using an alternative MIC test method** for ○ isolates testing cefazolin resistant (MIC ≥32 µg/ml) and cefuroxime susceptible (ETEST® XM256 MIC ≤4µg/ml) or intermediate (ETEST® XM256 MIC = 8 or 16 µg/ml) **(*) comment 19 of page 55 of CLSI M100 S26 – 2016**

bioMérieux UK Ltd

Grafton Way, Basingstoke, Hampshire, RG22 6HY
Tel.: +44 (0)1256 461881 - Fax: +44 (0)1256 816863 - www.biomerieux.co.uk
Registered Office: Grafton Way, Basingstoke, Hampshire, RG22 6HY – Registered in England No. 1061914

- Among tests previously performed, we are asking you to identify any possible false Susceptible results, analyze the related risks and determine appropriate actions if relevant.

- Contact your local bioMérieux representative for product compensation.

- Complete and return the Acknowledgement Form in Attachment A by Fax to confirm receipt of this notice.

bioMérieux is committed to providing our customers with the highest quality product possible. We sincerely apologize for any inconvenience that this may have caused you. If you require additional assistance or have any questions, please contact your local bioMérieux Customer Service representative.

Yours sincerely,
Customer Service

bioMérieux UK Ltd

Grafton Way, Basingstoke, Hampshire, RG22 6HY
Tel.: +44 (0)1256 461881 - Fax: +44 (0)1256 816863 - www.biomerieux.co.uk
Registered Office: Grafton Way, Basingstoke, Hampshire, RG22 6HY – Registered in England No. 1061914

Attachment A: Acknowledgement Form – FSCA3303

In order to comply with Competent Authority Regulations it is important that you complete and return this acknowledgement form

Please return for the attention of Customer Service to fax number 0044 (0) 1256 816863

❑ I acknowledge the receipt of bioMérieux Urgent Field Safety Notice informing this laboratory on the **ETEST® XM256 (Cefuroxime) Foam (Ref. 506958, 506918) and SPB (Ref. 412304, 412305)** product issue.

Reference	Description	Lot Number	Expiry date	Number of kits received	Number of kits destroyed
412304	**ETEST® XM256 (Cefuroxime)** US SPB	1004497830	02-Dec-18		
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1002884720	16-Jan-17		
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1003028270	20-Mar-17		
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1003075500	09-Apr-17		
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1003383650	27-Aug-17		
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1004018820	19-May-18		
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1004497810	02-Dec-18		
412305	**ETEST® XM256 (Cefuroxime)** WW SPB	1005161160	15-Sep-19		
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1002884980	16-Jan-17		
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1003028290	20-Mar-17		
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1003075850	09-Apr-17		
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1003385930	27-Aug-17		
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1003396150	02-Sep-17		
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1004022170	19-May-18		
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1004498100	02-Dec-18		
506918	**ETEST® XM256 (Cefuroxime)** WW Foam	1005161470	15-Sep-19		
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1002885010	16-Jan-17		
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1003075540	09-Apr-17		
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1003396550	02-Sep-17		
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1004019050	19-May-18		
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1004501930	02-Dec-18		
506958	**ETEST® XM256 (Cefuroxime)** US Foam	1005161480	15-Sep-19		

bioMérieux UK Ltd

Grafton Way, Basingstoke, Hampshire, RG22 6HY
Tel.: +44 (0)1256 461881 - Fax: +44 (0)1256 816863 - www.biomerieux.co.uk
Registered Office: Grafton Way, Basingstoke, Hampshire, RG22 6HY – Registered in England No. 1061914

❑ I have followed the instructions and implemented the actions as indicated in the Urgent Field Safety Notice.

Have you received reports of illness or injury related to the identified issue?
❑ Yes or ❑ No

NAME: .....
DATE.....
SIGNATURE : .....

bioMérieux UK Ltd

Grafton Way, Basingstoke, Hampshire, RG22 6HY
Tel.: +44 (0)1256 461881 - Fax: +44 (0)1256 816863 - www.biomerieux.co.uk
Registered Office: Grafton Way, Basingstoke, Hampshire, RG22 6HY – Registered in England No. 1061914